Abstract Background The Infectious Diseases Society of America is committed to providing
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …

Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …

Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global
pathogen with limited treatment options. No new antibiotic chemical class with activity …

Bacterial resistance to carbapenem agents has reached alarming levels. Accordingly,
collaborative efforts between national and international organizations and the …

Background Cefiderocol is a last resort option for carbapenem-resistant (CR) Gram-negative
bacteria, especially metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa and …

Carbapenems are potent members of the β-lactam family that inhibit bacterial cell-wall
biosynthesis inhibitors. They are highly effective against Gram-negative and Gram-positive …

Antimicrobial combinations are at the moment the only potential treatment option for
pandrug-resistant A. baumannii. A systematic review was conducted in PubMed and Scopus …

Objectives This study presents 2016–2018 in vitro antimicrobial activity data and rates of
resistant phenotypes for clinical isolates of Acinetobacter baumannii from Africa/Middle East …

Purpose Pending approval of new antimicrobials, synergistic combinations are the only
treatment option against pandrug-resistant A. baumannii (PDRAB). Considering the lack of a …

Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial
iron transport systems facilitating drug entry into cells, achieving high periplasmic …